此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

评估减少 TAVI 患者治疗时间的干预措施 (TREAT)

2026年11月3日 更新者:University Hospital, Rouen

Evaluation d'Une Intervention Pour Reduire le Delai de Traitement Des Patients Traites Par TAVI

Aortic stenosis (AS) is the most frequent valvulopathy in Western countries. The prevalence of AS is constantly increasing due to the aging of the population. Although significant progress has been made in understanding the pathophysiological mechanisms underlying the onset and progression of AS, there is no medical treatment to slow or prevent its progression. The only treatment available is Aortic Valve Replacement (AVR) performed by surgery or by catheterization (TAVI).

Once a diagnosis has been made and the decision to treat these patients has been taken, the procedure (AVR or TAVI) must be performed rapidly given the poor prognosis of the disease without treatment. Studies have shown that on the waiting list, the probability of death and hospitalisation for heart failure increases with time. This delay could also reduce the effectiveness of TAVI, thus affecting the performance of the healthcare system.

In this study, an intervention combining an e-health component (tool intended for patients, families and health professionals in contact with patients), and an organisational component (for TAVI implanting centres) has been designed. The aim of this study is to evaluate the effectiveness of this intervention.

研究概览

研究类型

介入性

注册 (实际的)

828

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Brest、法国
        • Brest University Hospital
      • Rouen、法国
        • CHU de Rouen

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Patient over 18 years of age;
  • Aortic stenosis
  • Indication of TAVI
  • Patient affiliated or benefiting from a health insurance scheme
  • Patient having read and understood the information letter and having signed the consent form

Exclusion Criteria:

  • TAVI indication not retained
  • Patient who are not fluent in French and have no one around them to translate,
  • Patient who do not have access to the Internet (at home or in their immediate environment)
  • Proven pregnant woman (positive urine pregnancy test) or breastfeeding or absence of effective contraception (as defined by the WHO) or postmenopausal woman without confirmation diagnosis obtained (amenorrhea not medically induced for at least 12 months before the initiation visit) ;
  • Person deprived of their liberty by an administrative or judicial decision or person placed under the protection of justice / guardianship or curators
  • History of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participating in the protocol or preventing him from giving his informed consent

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:其他
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
无干预:Control group

The randomized centres in this group will not change their practices.

实验性的:Patient component

The randomized centres in this group will be required to present patients with:

  • A short introductory video, viewed on a tablet during hospitalization for coronary angiography,
  • A paper booklet,
  • A website.

Video, booklet, website

实验性的:Organisational component

The randomized centres in this group will be provided with a list of organisational changes to be implemented to improve patient care times.

Coronarography, CT-scan, anesthesia...

实验性的:Patient and organisational components

The randomized centres in this group will have to implement the two components.

Video, booklet, website

Coronarography, CT-scan, anesthesia...

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
To evaluate the effectiveness of an intervention combining a patient component and an organisational component
大体时间:Month 6

Percentage of patients with a TAVI indication with a time to TAVI procedure of less than 2 months

Month 6

次要结果测量

结果测量
措施说明
大体时间
Time to care, in days
大体时间:Month 6

The time to care is the number of days between the date of the initial consultation during which a TAVI is proposed and the date of the TAVI procedure

Month 6
Mortality rate
大体时间:Months 3 and 6

The mortality rate will be measured between the initial consultation during which a TAVI is proposed and the TAVI procedure, and in the three months following the procedure

Months 3 and 6
Patients' health-related quality of life
大体时间:Baseline, Months 3 and 6

Patients' health-related quality of life will be measured using the 5-level EQ-5D version (EQ-5D-5L).

Baseline, Months 3 and 6
Patient knowledge of the disease and the TAVI procedure
大体时间:Baseline, Month 3

Patients' knowledge of the disease and the TAVI procedure will be measured by their score to an ad hoc questionnaire (0: minimum score - 26: maximum score).

Baseline, Month 3
Medication compliance
大体时间:Month 6

Patient medication compliance will be measured using a questionnaire developed by Girerd et al, with a score going from 0 (lowest compliance) to 6 (maximum compliance).

Month 6
Patient satisfaction
大体时间:Month 6

Patient satisfaction with the care they received and (for the group receiving the patient component) with the patient component of the intervention will be measured using a 0 to 10 Likert scale

Month 6
Number of visits to the patient section of the website
大体时间:Month 6

The number of visits to the website will be assessed through Googleanalytics®

Month 6
Number of visits to the professional section of the website
大体时间:Month 6

The number of visits to the website will be assessed through Googleanalytics®

Month 6
Acceptability of the intervention for participating centers
大体时间:Month 6

The acceptability of the intervention will be assessed through an ad hoc questionnaire addressed to TAVI centers and peripheral hospitals performing the coronary angiography of the pre-TAVI assessment.

Month 6
Intervention components' dose and fidelity
大体时间:Month 6

Number of different activities really performed for each component of the intervention / number of activities planned for each component according to the protocol.

Month 6
Reached populations
大体时间:Month 6

Percentage of target individuals who benefit from activities of each component of the intervention

Month 6
Intervention components' adaptation
大体时间:Month 6

Number of activities performed which have been modified to adapt them to the local context / total number of activities performed. A description of the adaptations performed will be provided.

Month 6
Incremental cost-effectiveness ratio
大体时间:Month 6

The incremental cost-effectiveness ratio will be expressed in cost per quality-adjusted life-year (QALY) gained, derived from the EQ-5D-5L questionnaire

Month 6

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Helene Eltchaninoff, Pr、University Hospital, Rouen

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2022年10月26日

初级完成 (实际的)

2025年10月23日

研究完成 (实际的)

2025年10月23日

研究注册日期

首次提交

2021年12月23日

首先提交符合 QC 标准的

2022年2月11日

首次发布 (实际的)

2022年2月14日

研究记录更新

最后更新发布 (实际的)

2026年11月6日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年2月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅